Employees in the India headquarters of Foxx Life Sciences. Courtesy photo.
With a burgeoning market in Asia, Salem-based Foxx Life Sciences, a manufacturer and supplier of single-use biotech disposables, is opening a headquarters in India and launching a website foxxlifesciences.in for those customers.
“The India market is growing 25% for biopharmaceutical. We want to be the first one with strong manufacturing and distribution capability in that region,” says Thomas Taylor, president and CEO.
After six years of planning, development and construction, the 20,000-square-foot facility in India will has warehouse and manufacturing space to serve customers across Southeast Asia.
Foxx Life Sciences has customers in more than 30 countries and is an exclusive North American distributor for several Indian manufacturers.
Eknath Kulkarni, managing director of Foxx Life Sciences, India, says the new facility has 15 employees though they are looking to hire sales, manufacturing and engineering personnel for that location. “We can develop local products for the India market and support American customers as well,” Kulkarni says. “We are developing our brand for India and Asia.”
Foxx, which launched in 2008, has grown sales 40% annually for eight of the past nine years and nearly doubled its workforce to 100 employees in the past 30 months. The company either manufactures or distributes more than 4,600 products, including laboratory filtration, lab safety and lab glassware for biotech and biopharmaceutical firms.
The family-owned business (Taylor’s wife, Alice Molteni Taylor, is director of bioProcess sales), opened a second NH location in 2019 in Londonderry—a 75,000-square-foot building near Manchester-Boston Regional Airport, UPS, and FedEx. Thomas Taylor says that facility has spurred growth.
From left: Greg Bousquet, COO; Thomas Taylor, president and CEO; and Stephanie Aznoian, CFO.
Taylor also brought on new executive talent, including a CFO, COO, and senior vice president of global sales in 2019 and 2020. “They have a lot of experience,” Taylor says. “To continue to grow at 40% per year we knew we needed to bring in a senior team to help me scale it.”
Of course, the company has felt the effects of COVID-19, losing 25% of its research lab business when colleges and universities shutdown or went virtual. And there have been global interruptions to its supply chain. However, Foxx also found opportunity as labs worldwide rushed to develop a vaccine, spiking orders in that sector by more than 90%, Taylor says. It added PPE to its product line and produced 100,000 FDA-registered COVID test kits in Q4 2020. “We have orders of over 500,000 units for 2021,” Taylor says, adding they have the capacity to produce more.
For more information, visit foxxlifesciences.com.
Current Issue - April 2024